SNN

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

High

28.780

Open

28.510

VWAP

28.67

Vol

685.00K

Mkt Cap

12.59B

Low

28.440

Amount

19.64M

EV/EBITDA(TTM)

10.10

Total Shares

875.94M

15.01B

EV/OCF(TTM)

15.21

P/S(TTM)

2.11

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2029Q1

FY2029Q2

FY2029Q3

1.52B

+5.6%

1.51B

+6.79%

1.68B

+6.96%

Estimates Revision

The market is revising Upward the revenue expectations for Smith & Nephew plc (SNN) for FY2025, with the revenue forecasts being adjusted by 0.92% over the past three months. During the same period, the stock price has changed by 10.79%.

Revenue Estimates for FY2025

Revise Upward

+0.92%

In Past 3 Month

Stock Price

Go Up

+10.79%

In Past 3 Month

3 Analyst Rating

0.17% Upside

Wall Street analysts forecast SNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNN is 28.80 USD with a low forecast of 27.71 USD and a high forecast of 30.70 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

0.17% Upside

Current: 28.750

Low

27.71

Averages

28.80

High

30.70

0.17% Upside

Current: 28.750

Low

27.71

Averages

28.80

High

30.70

Canaccord Genuity

Caitlin Cronin

Hold

Maintains

$27 → $28

2025-05-01

Reason

Canaccord Genuity

Caitlin Cronin

Price Target

$27 → $28

2025-05-01

Maintains

Hold

Reason

Canaccord analyst Caitlin Cronin raised the firm's price target on Smith & Nephew to $28 from $27 and keeps a Hold rating on the shares. The firm said they delivered a solid Q1 overall, slightly beating consensus and maintaining its guidance through the P&L. The company saw similar LSD reported growth across its portfolio segments as China headwinds which it believes have peaked, and one fewer selling day impacted growth as anticipated.

Canaccord Genuity

Caitlin Cronin

Hold

Maintains

$27

2025-03-17

Reason

Canaccord Genuity

Caitlin Cronin

Price Target

$27

2025-03-17

Maintains

Hold

Reason

UBS

Graham Doyle

Strong Buy

Hold

Downgrades

n/a

2025-03-12

Reason

UBS

Graham Doyle

Price Target

n/a

2025-03-12

Downgrades

Strong Buy

Hold

Reason

Canaccord Genuity

Kyle Rose

Hold

Maintains

$27

2025-02-26

Reason

Canaccord Genuity

Kyle Rose

Price Target

$27

2025-02-26

Maintains

Hold

Reason

UBS

Graham Doyle

Hold

Strong Buy

Upgrades

n/a

2024-06-05

Reason

UBS

Graham Doyle

Price Target

n/a

2024-06-05

Upgrades

Hold

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Smith & Nephew PLC (SNN.N) is 14.06, compared to its 5-year average forward P/E of 18.37. For a more detailed relative valuation and DCF analysis to assess Smith & Nephew PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

18.37

Current PE

14.06

Overvalued PE

22.27

Undervalued PE

14.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

11.46

Current EV/EBITDA

9.65

Overvalued EV/EBITDA

13.57

Undervalued EV/EBITDA

9.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

2.53

Current PS

2.01

Overvalued PS

3.15

Undervalued PS

1.90